169 related articles for article (PubMed ID: 32826248)
1. Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Seydafkan S; Michl J; Pincus MR
Ann Clin Lab Sci; 2020 Jul; 50(4):504-511. PubMed ID: 32826248
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
[TBL] [Abstract][Full Text] [Related]
3. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
5. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
6. The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.
Izumi K; Ikeda H; Maolake A; Machioka K; Nohara T; Narimoto K; Ueno S; Kadono Y; Kitagawa Y; Konaka H; Mizokami A; Namiki M
Prostate; 2015 Jul; 75(10):1034-42. PubMed ID: 25753899
[TBL] [Abstract][Full Text] [Related]
7. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
8. Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade.
Venkatesan AM; Mudairu-Dawodu E; Duran C; Stafford RJ; Yan Y; Wei W; Kundra V
Cancer Imaging; 2021 Jan; 21(1):3. PubMed ID: 33407861
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
10. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
11. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
12. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
14. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
15. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
17. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
[TBL] [Abstract][Full Text] [Related]
18. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Horninger W; Klocker H; Mikolajczyk SD
J Urol; 2004 Jun; 171(6 Pt 1):2239-44. PubMed ID: 15126794
[TBL] [Abstract][Full Text] [Related]
19. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
Dimmen M; Vlatkovic L; Hole KH; Nesland JM; Brennhovd B; Axcrona K
BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
